Skip to main content
OpenTrials
Completed

NCT Number: NCT01785095

Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles

The purpose of the study is to evaluate immunogenic potential of FSH-IBSA in healthy volunteers undergoing controlled ovarian hyperstimulation (COH) in an oocyte donation program.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Dep.Obstet-Gynec.-Reproduction,Institut Universitari Dexeus

Barcelona, 8028, Spain

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy female volunteers undergoing controlled ovarian hyperstimulation for oocyte donation with the following characteristics:
  • Able and willing to sign the Subject Consent Form and adhere to the study visit schedule;
  • >=18 and <35 years old;
  • Regular menstrual cycle (26 - 35 days);
  • BMI between 18 and 30 kg/m2;
  • First gonadotrophin treatment (i.e. naïve Subjects with regard to exposure to human derived or recombinant gonadotrophins);
  • basal FSH <10 IU/L and E2 <80 pg/ml (~290 pmol/l);
  • Normal TSH levels;
  • Willing to perform at least two consecutive oocyte retrieval cycles (with a wash out period of two months).

Exclusion criteria

  • Age <18 and >=35 years;
  • PCOS;
  • Endometriosis;
  • Subjects with evidences of autoimmune or rheumatic diseases;
  • Hypersensitivity to the active substance or to any of the excipients (lactose);
  • Abnormal bleeding of undetermined origin;
  • Subject found to be positive to anti-TSH antibodies (i.e. suffering from thyroidal diseases);
  • Uncontrolled adrenal dysfunction;
  • Neoplasia;
  • Severe impairment of renal and/or hepatic function;
  • Use of concomitant medications that might interfere with study evaluations (e.g. immunosuppressant, non-study hormonal medications, therapeutics proteins like insulin, growth hormone…).

Treatment and study plan

FSH (Follicle Stimulating Hormone)

Drug

Primary outcomes

  1. Number of Patients Producing Anti-FSH Antibodies.

    Time frame: 4 months.

    The immunogenicity potential of FSH in healthy volunteer will be assessed by analysing serum samples collected at different timepoints during two treatment cycle for oocytes donation: cycle 1, serum samples will be collected before treatment start (baseline), after 7-13 days and after 28 days of treatment; Cycle 2: serum samples will be collected before starting the second cycle (baseline 2), after 7-13 days and after 28 days of treatment. Cycle 1 and cycle 2 will be separated by a wash-out period of two months.

Secondary outcomes

  1. Number of Oocytes Retrieved

    Time frame: after 2 weeks of treatment

    the number of oocytes retrieved in the first cycle and in the second cycle are compared.

  2. Total Dose of FSH Units Used.

    Time frame: after 2 weeks of treatment

Sponsors and collaborators

Lead sponsor

IBSA Institut Biochimique SA

Industry

Registry information

Official study title

Prospective, Open-label, Uncontrolled Clinical Trial Evaluating Multiple Controlled Ovarian Hyperstimulation Cycles in Oocyte Donor, to Assess the Immunogenicity of FSH-IBSA

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Feb 7, 2013
Registry last updated
Feb 9, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.